Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

The Cipla share declined 6.02 per cent on Monday to settle at ₹964.05 apiece on the BSE 

Cipla shares fall over 6% due to this reason 

The Cipla share declined 6.02 per cent on Monday to settle at ₹964.05 apiece on the BSE&nbsp;

Shares of Cipla on Monday ended over 6 per cent lower after the company received 'Form 483' with eight observations for its Pithampur-based manufacturing facility.
The stock declined 6.02 per cent to settle at Rs 964.05 apiece on the BSE. During the day, it tumbled 6.78 per cent to Rs 956.20.
On the NSE, it tanked 6.11 per cent to end at Rs 963 per share.
In volume terms, 2.38 lakh shares were traded on the BSE and over 58.29 lakh shares on the NSE during the day.
The US Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from February 6-17, the Mumbai-based drug firm said in a regulatory filing on Saturday.
On conclusion of the inspection, the company has received eight inspectional observations in Form 483, it added.
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time, it said.
As per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&amp;C) Act and related Acts.

India has granted Emergency Use Authorisation (EUA) to antiviral Covid-19 pill molnupiravir. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate covid at high risk of developing severe disease.
The pill is administered as four 200 milligram capsules taken orally every 12 hours for five days, for a total of 40 capsules. Molnupiravir is not authorised for use for longer than five consecutive days.
Cipla plans to launch Molnupiravir under the brand name Cipmolnu. The pharma informed exchanges stating, "Cipla will soon make Cipmolnu® 200mg capsules available at all leading pharmacies and Covid treatment centers across the country. The Company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan India." The drug developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US Pharma giant Merck will now be manufactured by 13 Indian drug manufacturers as per Health Ministry. 

Cipla to launch covid pill Molnupiravir in India

The drug developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US Pharma giant Merck 

Cipla to launch covid pill Molnupiravir in India, here is what you need to know about the drug

The drug developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US Pharma giant Merck&nbsp;

India has granted Emergency Use Authorisation (EUA) to antiviral Covid-19 pill molnupiravir.&nbsp;Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate covid at high risk of developing severe disease.
The pill is administered as four 200 milligram capsules taken orally every 12 hours for five days, for a total of 40 capsules. Molnupiravir is not authorised for use for longer than five consecutive days.
Also watch |&nbsp;<a title="Covid-19 surge: More restrictions to be announced in Delhi, says CM Kejriwal" href="https://www.editorji.com/india-news/covid-19-surge-more-restrictions-to-be-announced-in-delhi-says-cm-kejriwal-1640678253201">Covid-19 surge: More restrictions to be announced in Delhi, says CM Kejriwal</a>
Cipla plans to launch Molnupiravir under the brand name Cipmolnu. The pharma&nbsp;informed exchanges stating, "Cipla will soon make Cipmolnu&reg; 200mg capsules available at all leading pharmacies and Covid treatment centers across the country. The Company has adequate manufacturing capacities and a solid distribution mechanism in place to ensure speedy access to this effective treatment pan India."&nbsp; The drug developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US Pharma giant Merck will now be manufactured by 13 Indian drug manufacturers as per Health Ministry.&nbsp;

Coronavirus is soon going to be endemic for us, Umang Vohra, Global CEO &amp; MD of Cipla said in an exclusive chat with Editorji and Fortune India.
"Covid&nbsp;is not going to be any different from any other Flu, so it is going to be there in the society. When people get it they will have to isolate for 10-12 days," Vohra&nbsp;pointed out.
He also mentioned that antibodies will have a great role to play after the pandemic ends.

On Biz Buzz | Cipla CEO Exclusive, Covid boosters not 'true boosters'

Coronavirus is soon going to be endemic for us, Umang Vohra, Global CEO & MD of Cipla said in an exclusive chat with Editorji and Fortune India as he prescribes the road ahead for the company. 

Cipla CEO Exclusive | Covid boosters not 'true boosters'

Coronavirus is soon going to be endemic for us, Umang Vohra, Global CEO &amp; MD of Cipla said in an exclusive chat with Editorji and Fortune India.
"Covid&nbsp;is not going to be any different from any other Flu, so it is going to be there in the society. When people get it they will have to isolate for 10-12 days," Vohra&nbsp;pointed out.
He also mentioned that antibodies will have a great role to play after the pandemic ends.

<ul>
<li>Covid&nbsp;is not going to be any different from any other Flu</li>
</ul>

The pandemic has led to a faster process in rolling out the right drug into the market, as pointed out by&nbsp;Umang Vohra, Global CEO &amp; MD of Cipla.
In an exclusive conversation with Editorji&nbsp;and Fortune India, Vohra&nbsp;mentioned that&nbsp;data science and technology&nbsp;are allowing to match a prediction with the evidence really quickly.
"What took years to put together in terms of computational&nbsp;power, now just takes 10% of the time," Cipla's&nbsp;Global CEO&nbsp;told Editorji.
&nbsp;

Cipla CEO Exclusive | Game changing moves in approvals and discovery 

The pandemic has led to a faster process in rolling out the right drug into the market, as pointed out by Umang Vohra, Global CEO & MD of Cipla.

The pandemic has led to a faster process in rolling out the right drug into the market, as pointed out by&nbsp;Umang Vohra, Global CEO &amp; MD of Cipla.
In an exclusive conversation with Editorji&nbsp;and Fortune India, Vohra&nbsp;mentioned that&nbsp;data science and technology&nbsp;are allowing to match a prediction with the evidence really quickly.
"What took years to put together in terms of computational&nbsp;power, now just takes 10% of the time," Cipla's&nbsp;Global CEO&nbsp;told Editorji.
&nbsp;

What took years to put together in terms of computational&nbsp;power, now just takes 10% of the time

As the pharma industry makes the transition for the world to move from &nbsp;&lsquo;illness to wellness&rsquo; Umang Vohra, Global CEO &amp; MD of Cipla says innovation not generics will be the next big bet for the sector.In an exclusive chat with Editorji&nbsp;and Fortune India Cipla's&nbsp;Global CEO&nbsp;&amp; MD says he expects to see over 70% of Indians vaccinated by June 2022 and is confident that Covid will become just another flu the world will learn to live with.On the question of boosters, the Cipla chief says the current dose of boosters are not &rsquo;true boosters&rsquo; and are largely just an extra shot as the virus continues to mutate.&nbsp;

On Biz Buzz| Cipla Global CEO Exclusive on global partnerships and pharma beyond covid

Umang Vohra Global MD & CEO, @Cipla_Global in an exclusive chat sees a paradigm shift for the sector as it moves from  just curing illness to the 'wellness ecosystem' with game changing partnerships. 

#BizBuzz | Cipla on Covid & Beyond

Global collaboration now in pharma is a paradigm shift for innovation: Cipla&nbsp;

As the pharma industry makes the transition for the world to move from &nbsp;&lsquo;illness to wellness&rsquo; Umang Vohra, Global CEO &amp; MD of Cipla says innovation not generics will be the next big bet for the sector. In an exclusive chat with Editorji&nbsp;and Fortune India Cipla's&nbsp;Global CEO&nbsp;&amp; MD says he expects to see over 70% of Indians vaccinated by June 2022 and is confident that Covid will become just another flu the world will learn to live with. On the question of boosters, the Cipla chief says the current dose of boosters are not &rsquo;true boosters&rsquo; and are largely just an extra shot as the virus continues to mutate.&nbsp;

Cipla&nbsp;has got the nod from the DCGI&nbsp;to import Moderna's&nbsp;Covid&nbsp;19 vaccine into India as per reports.&nbsp;Cipla had sought DGCI's permission for importing and marketing authorisation of Moderna&rsquo;s coronavirus vaccine earlier on Tuesday.&nbsp;. It will be the fourth vaccine to be administered in India after Covishield, Covaxin and Sputnik V.Moderna has proposed to launch a single-dose vaccine for the Indian market. Cipla&nbsp;has not yet confirmed a supply agreement with Moderna&nbsp;though the company said the logistics and storage are already in place for importing the vaccine.&nbsp;Moderna&nbsp; has an&nbsp;mRNA-based vaccine with an efficacy rate of 94.1 percent, according to WHO estimate.

Cipla gets nod to import Moderna Covid 19 vaccine

Gear up for vaccine number 4, Drug regulator gives Cipla&nbsp;the nod to import Moderna's&nbsp;Covid&nbsp;19 vaccine

Vaccine No. 4 is here 

Cipla&nbsp;has got the nod from the DCGI&nbsp;to import Moderna's&nbsp;Covid&nbsp;19 vaccine into India as per reports.&nbsp;
Cipla had sought DGCI's permission for importing and marketing authorisation of Moderna&rsquo;s coronavirus vaccine earlier on Tuesday.&nbsp;. It will be the fourth vaccine to be administered in India after Covishield, Covaxin and Sputnik V.
Moderna has proposed to launch a single-dose vaccine for the Indian market. Cipla&nbsp;has not yet confirmed a supply agreement with Moderna&nbsp;though the company said the logistics and storage are already in place for importing the vaccine.&nbsp;
Moderna&nbsp; has an&nbsp;mRNA-based vaccine with an efficacy rate of 94.1 percent, according to WHO estimate.

Drugs Controller General of India&rsquo;s (DCGI) has give the nod to import Moderna's COVID-19 vaccine for restricted emergency use in India.&nbsp;

Cipla&nbsp;has got the nod from the DCGI&nbsp;to import Moderna's&nbsp;Covid&nbsp;19 vaccine into India.&nbsp; Cipla had sought DGCI's permission for importing and marketing authorisation of Moderna&rsquo;s coronavirus vaccine earlier on Tuesday.&nbsp;. It will be the fourth vaccine to be administered in India after Covishield, Covaxin and Sputnik V. Moderna has proposed to launch a single-dose vaccine for the Indian market. Cipla&nbsp;has not yet confirmed a supply agreement with Moderna&nbsp;though the company said the logistics and storage are already in place for importing the vaccine.&nbsp; Moderna&nbsp; has an&nbsp;mRNA-based vaccine with an efficacy rate of 94.1 percent, according to WHO estimate. Read Also: <a href="https://www.edtr.ai/9q00">Why Covishield&nbsp;is not on the vaccine passport list for EU</a>

The indemnity roadblock set to be removed paving the way for Pfizer, Moderna&nbsp;vaccines to be imported into India. Reports indicate that the govt is gearing to grant indemnity&nbsp;from legal liability to the pharma&nbsp;giants.&nbsp;Pfizer who has stated that they have 5 crore&nbsp;doses ready to be imported into India had demanded an indemnity clause to finalise the deal. Such a clause absolves the pharma&nbsp;major from any legal liability in case of any adverse effects. Cipla also had approached the govt seeking the same for Moderna&nbsp;as the company is looking to import 50 million doses of the vaccine as they become available.&nbsp;

Indemnity roadblock set to be removed, paving the way for Pfizer

Indemnity roadblock set to be removed, paving the way for Pfizer vaccine

The indemnity roadblock set to be removed paving the way for Pfizer, Moderna&nbsp;vaccines to be imported into India. Reports indicate that the govt is gearing to grant indemnity&nbsp;from legal liability to the pharma&nbsp;giants.&nbsp; Pfizer who has stated that they have 5 crore&nbsp;doses ready to be imported into India had demanded an indemnity clause to finalise the deal. Such a clause absolves the pharma&nbsp;major from any legal liability in case of any adverse effects. Cipla also had approached the govt seeking the same for Moderna&nbsp;as the company is looking to import 50 million doses of the vaccine as they become available.&nbsp;

Pharma giant Cipla is set to commit $1 billion in importing Moderna vaccines into India but is awaiting clarity from the government. PTI reports that Cipla is seeking fast track approvals to bring Moderna's single-dose COVID-19 booster vaccine&nbsp;but is seeking waivers from the government of key clauses. As per unnamed sources&nbsp; to PTI Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty. Cipla has shown interest to procure 50 million doses from Moderna for 2022. Cipla has sought the government's assurance that no price capping would apply for imported vaccines to be provided through private hospitals and that the booster vaccine can be covered under the liberalised pricing policy and kept exempt from any price capping.&nbsp;

Cipla to import $1 billion of Moderna vaccine, seeks clarity from govt

Cipla to import $1 billion of Moderna vaccine, seeks clarity from govt on price capping, bridge trials and the stick indemnity.&nbsp;

Vaccine Update

Pharma giant Cipla is set to commit $1 billion in importing Moderna vaccines into India but is awaiting clarity from the government. PTI reports that Cipla is seeking fast track approvals to bring Moderna's single-dose COVID-19 booster vaccine&nbsp;but is seeking waivers from the government of key clauses. As per unnamed sources&nbsp; to PTI Cipla has requested the government for indemnification and exemptions from price capping, bridging trials and basic customs duty. Cipla has shown interest to procure 50 million doses from Moderna for 2022. Cipla has sought the government's assurance that no price capping would apply for imported vaccines to be provided through private hospitals and that the booster vaccine can be covered under the liberalised pricing policy and kept exempt from any price capping.&nbsp;

US pharma&nbsp;giant&nbsp;Moderna is expecting to launch a single-dose Covid-19 vaccine in India next year and is in talks with Cipla among other drugmakers, PTI has reported. The report said that Cipla has already evinced interest in procuring 5 crore doses from Moderna for 2022 and has requested confirmation from the central government in respect of stability in regulatory regime. The Health Ministry has also been asked to take an early decision on Cipla's request regarding support required by them for procurement of Moderna vaccines. Currently, the country is using two "made-in India" jabs -- Covishield and Covaxin -- to inoculate its billion-plus population and has administered 20 crore doses since launching the world's largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.

Moderna may launch single-dose Covid vaccine in India next year

US pharma&nbsp;giant&nbsp;Moderna is expecting to launch a single-dose Covid-19 vaccine in India next year

US pharma&nbsp;giant&nbsp;Moderna is expecting to launch a single-dose Covid-19 vaccine in India next year and is in talks with Cipla among other drugmakers, PTI has reported. The report said that Cipla has already evinced interest in procuring 5 crore doses from Moderna for 2022 and has requested confirmation from the central government in respect of stability in regulatory regime. The Health Ministry has also been asked to take an early decision on Cipla's request regarding support required by them for procurement of Moderna vaccines. Currently, the country is using two "made-in India" jabs -- Covishield and Covaxin -- to inoculate its billion-plus population and has administered 20 crore doses since launching the world's largest vaccination drive in mid-January. A third vaccine, Russian-made Sputnik V, has been approved by the government and is being used on a smaller scale at present.

Drug majors Roche India and Cipla on Monday announced launch of Roche's Antibody Cocktail in India for the treatment of mild to moderate Covid-19 in patients who are at high risk.
The Antibody Cocktail, which is a mix of Casirivimab and Imdevimab, is priced at Rs 59,750 per dose.
The drugmakers said that the first batch of the Antibody Cocktail is now available in India while a second batch will be made available by mid-June.
"In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients," Cipla and Roche said in a joint statement. The drug will be available through leading hospitals and Covid treatment centres.
The Central Drugs Standards Control Organisation had recently provided an emergency use authorisation for the Antibody Cocktail in India. It has also received nod in the US and several EU countries.
The antibody cocktail is to be administered for the treatment of mild to moderate Covid-19 in adults and kids above 12 years of age.
The has shown to reduce the risk of hospitalisation and fatality by 70 per cent and shortening the duration of symptoms by four days, Cipla and Roche said.

Covid Antibody Cocktail launched in India. Here's all you need to know

Drug majors Roche India and Cipla on Monday announced launch of Roche's Antibody Cocktail in India for the treatment of mild to moderate Covid-19. Here's all you need to know

Drug majors Roche India and Cipla on Monday announced launch of Roche's Antibody Cocktail in India for the treatment of mild to moderate Covid-19 in patients who are at high risk.
The Antibody Cocktail, which is a mix of Casirivimab and Imdevimab, is priced at Rs 59,750 per dose.
The drugmakers said that the first batch of the Antibody Cocktail is now available in India while a second batch will be made available by mid-June.
"In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients," Cipla and Roche said in a joint statement. The drug will be available through leading hospitals and Covid treatment centers.
The Central Drugs Standards Control Organisation had recently provided an emergency use authorisation for the Antibody Cocktail in India. It has also received nod in the US and several EU countries.
The antibody cocktail is to be administered for the treatment of mild to moderate Covid-19 in adults and kids above 12 years of age.
The has shown to reduce the risk of hospitalisation and fatality by 70 per cent and shortening the duration of symptoms by four days, Cipla and Roche said.

Drug majors Roche India and Cipla on Monday announced launch of Roche's Antibody Cocktail in India for the treatment of mild to moderate Covid-19 in patients who are at high risk.
The Antibody Cocktail, which is a mix of Casirivimab and Imdevimab, is priced at Rs 59,750 per dose.
The drugmakers said that the first batch of the Antibody Cocktail is now available in India while a second batch will be made available by mid-June.
"In total they can potentially benefit 2,00,000 patients as each of the 1,00,000 packs that will be available in India offers treatment for two patients," Cipla and Roche said in a joint statement. The drug will be available through leading hospitals and Covid treatment centres.
The Central Drugs Standards Control Organisation had recently provided an emergency use authorisation for the Antibody Cocktail in India. It has also received nod in the US and several EU countries.
The antibody cocktail is to be administered for the treatment of mild to moderate Covid-19 in adults and kids above 12 years of age.
The has shown to reduce the risk of hospitalisation and fatality by 70 per cent and shortening the duration of symptoms by four days, Cipla and Roche said.

Cipla has doubled production of COVID-19 medication Remdesivir to help meet &ldquo;unprecedented demand&rdquo; .&nbsp; The recent spike in COVID-19 cases and hospitalizations has lead to an increase in demand for the drug as it is used to treat patients with severe complications.
"We have scaled up the production of Remdesivir by 2x from the last wave of the pandemic. Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network, to service the demand," Cipla said in a statement
The shortage in the market has been severe, in a letter to the Drug Controller General of India (DCGI), LocalCircles pointed out that over the last week, many posts and comments received from various cities of India have quoted the drug selling for as high as Rs 50,000 over 10 times of the retail price of the drug.

Cipla doubles up Remdesivir production as shortage continues

Mumbai&nbsp;based pharma&nbsp;major Cipla has&nbsp;doubled up Remdesivir production as nation-wide shortage continues

Cipla doubles up Remdesivir production

Cipla has doubled production of COVID-19 medication Remdesivir to help meet &ldquo;unprecedented demand&rdquo;.&nbsp; The recent spike in COVID-19 cases and hospitalizations has lead to an increase in demand for the drug as it is used to treat patients with severe complications. The shortage in the market has been such severe that in various cities the drug is being sold for as high as Rs 50,000, which is over 10 times of the retail price of the drug.
<ul>
<li>&nbsp;</li>
<li>Cipla&nbsp;doubles up production of&nbsp;Remdesivir&nbsp;as demand surges&nbsp;</li>
<li>Shortage of&nbsp;Remdesivir&nbsp;across the nation especially Maharashtra&nbsp;</li>
<li>Remdesivir&nbsp;is anti-viral used to treat patients with severe complications</li>
<li>Reports indicated the black market price for&nbsp;Remdesivir&nbsp;was 10 fold to MRP</li>
</ul>

Cipla has doubled production of COVID-19 medication Remdesivir to help meet &ldquo;unprecedented demand&rdquo; .&nbsp; The recent spike in COVID-19 cases and hospitalizations has lead to an increase in demand for the drug as it is used to treat patients with severe complications.
 "We have scaled up the production of Remdesivir by 2x from the last wave of the pandemic. Given the unprecedented demand for the drug, we have now further ramped up our capacities through our network, to service the demand," Cipla said in a statement
The shortage in the market has been severe, in a letter to the Drug Controller General of India (DCGI), LocalCircles pointed out that over the last week, many posts and comments received from various cities of India have quoted the drug selling for as high as Rs 50,000 over 10 times of the retail price of the drug.

Sensex, Nifty almost flat in morning trade

Stock markets were flat in the opening session on Tuesday tracking mixed Asian peers.
At 9:25 am, the Sensex was at 38,388, down 28 points and the Nifty was trading 0.07% in the red at 11,347.
Infratel, Tata&nbsp;Motors, Grasim, HDFC&nbsp;and Zee&nbsp;were the top five Nifty losers. While DrReddy, BPCL, Cipla, Hero Moto&nbsp;Corp and Infosys were the top gainers.

38,388.88 -28.35 -0.07%
11,347.30
 -7.75&nbsp;-0.07%&nbsp;

Stock markets were flat in the opening session on Tuesday tracking mixed Asian peers.
At 9:25 am, the Sensex was at 38,388, down 28 points and the Nifty was trading 0.07% in the red at 11,347.
Infratel, Tata&nbsp;Motors, Grasim, HDFC&nbsp;and Zee&nbsp;were the top five Nifty losers. While DrReddy, BPCL, Cipla, Hero Moto&nbsp;Corp and Infosys were the top gainers.

cipla

Categories